ArticleSleep advances : a journal of the Sleep Research Society2021
Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies.
Article in Sleep advances : a journal of the Sleep Research Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Early detection of diseases causing dementia using digital navigation and gait measures: A systematic review of evidence.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Pooled it
- Longitudinal associations of rest-activity rhythms with executive function, plasma biomarkers, and clinical outcomes in older adults.Frontiers in aging neuroscience · 2026Article
- Big data approaches for novel mechanistic insights on sleep and circadian rhythms: a workshop summary.Sleep · 2025Article
- Using Apple Watches to Monitor Health and Behaviors of Individuals With Cognitive Impairment: A Case Series Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Article
- Circadian rhythms are associated with higher amyloid-β and tau and poorer cognition in older adults.Brain communications · 2025Article
- Data Analytics in Physical Activity Studies With Accelerometers: Scoping Review.Journal of medical Internet research · 2024Article
- Differences in Daily Physical Activity by Alzheimer's Risk Markers Among Older Adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
- Evaluating a novel 24-hour rest/activity rhythm marker of preclinical β-amyloid deposition.Sleep · 2024Article
- Sleep and circadian rhythm disruptions in behavioral variant frontotemporal dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspective.Orphanet journal of rare diseases · 2023Review
- Circadian disruption and sleep disorders in neurodegeneration.Translational neurodegeneration · 2023Review
- Wrist accelerometry for monitoring dementia agitation behaviour in clinical settings: A scoping review.Frontiers in psychiatry · 2022Article
- Day-to-day sleep variability with Alzheimer's biomarkers in at-risk elderly.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Night-to-night variability in sleep and amyloid beta burden in normal aging.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 1 country.
Funding
Abstract
STUDY
objectivesTo examine in a subsample at the screening phase of a clinical trial of a β-amyloid (Aβ) antibody whether disturbed sleep and altered 24-hour rest/activity rhythms (RARs) may serve as markers of preclinical Alzheimer's disease (AD).
methodsOverall, 26 Aβ-positive (Aβ+) and 33 Aβ-negative (Aβ-) cognitively unimpaired participants (mean age = 71.3 ± 4.6 years, 59% women) from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) and the Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies, respectively, wore actigraphs for 5.66 ± 0.88 24-hour periods. We computed standard sleep parameters, standard RAR metrics (mean estimating statistic of rhythm, amplitude, acrophase, interdaily stability, intradaily variability, relative amplitude), and performed a novel RAR analysis (function-on-scalar regression [FOSR]).
resultsWe were unable to detect any differences between Aβ+ and Aβ- participants in standard sleep parameters or RAR metrics with our sample size. When we used novel FOSR methods, however, Aβ+ participants had lower activity levels than Aβ- participants in the late night through early morning (11:30 pm to 3:00 am), and higher levels in the early morning (4:30 am to 8:30 am) and from midday through late afternoon (12:30 pm to 5:30 pm; all
conclusionsAlthough we found no association of preclinical AD with standard actigraphic sleep or RAR metrics, a novel data-driven analytic method identified temporally "local" RAR alterations in preclinical AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.